• Luan Wen, Ting He, AXiang Yu, Siqi Sun, Xiang Li, Jing Wei, Ruolan Song, Xin Yan, Ruiwen Li, Xueyang Ren, Yu Wang, Xiaoyun Liu, Ying Dong, Xueyan Fu, and Gaimei She.
• School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, P. R. China.
• Am. J. Chin. Med. 2021 Jan 1; 49 (6): 1369-1397.

AbstractBreviscapine is one of the extracts of several flavonoids of Erigeron breviscapus. Scutellarin is the main active component of breviscapine, and the qualitative or quantitative criteria as well. Scutellarin and its analogs share a similar skeleton of the flavonoids. Breviscapine has been widely used in the treatment of cerebral infarction and its sequelae, cerebral thrombus, coronary heart disease (CHD), and angina pectoris. Breviscapine has a broad spectrum of pharmacological activities, such as increasing blood flow, improving microcirculation, dilating blood vessels, decreasing blood viscosity, promoting fibrinolysis, inhibiting platelet aggregation, and thrombosis formation, etc. In addition, breviscapine and its analogs have significant value for drug research and development because of the superiority of those significant bioactivities. Furthermore, an increasing number of pharmacokinetic studies have explored the mechanism of scutellarin and its analogs. To provide a comprehensive understanding of the current research on breviscapine, scutellarin, and the analogs, the structural features, distribution situation, preparation method, content determination method, clinical applications, pharmacological action as well as pharmacokinetics are summarized in the present review.

22 keywords...

hide…